WELTRUZA™ (olanzapine) Approval – Conference Call - TEVA PHARMACEUTICAL INDUSTRIES LTD

Explicit Guidance:

• Revenue: Forecasted combined peak annual revenue of $1.5 billion to $2.0 billion for the Yosedi (paliperidone palmitate 3-month) and Welltrusa (olanzapine) franchise; specific guidance for Welltrusa alone is not provided, but the franchise target implies significant contribution from the new launch.
• Timing: Meaningful revenue contribution from Welltrusa is not expected in the first half of the following year; revenue ramp is anticipated to begin in the second half of the following year due to payer access timing.

Business-Segment Outlook:

• Launch & Penetration: Targeting the ~2.2 million U.S. schizophrenia patient population (1.5 million treated), with an initial focus on the 20% of the market currently on oral olanzapine for whom conversion to Long-Acting Injectables (LAIs) is expected to be the primary driver.
• Co-Location Strategy: Planning to leverage the existing Uzeti sales force and patient support infrastructure (Uzedi program) to cover approximately 80% of the schizophrenia continuum, targeting oral olanzapine, oral paliperidone, and oral risperidone patients.
• Pipeline/Indications: Potential for future label expansion into bipolar mania for the olanzapine LAI, pending additional studies similar to the modeling and simulation approach used for Uzeti's current indications.
• Patient Flow: Primary patient acquisition expected to come from "unstable" oral olanzapine patients (non-adherent, high relapse risk) rather than switches from other LAIs, though some cross-over from other LAIs is anticipated.

Market and Competitive Outlook:

• Adherence & Relapse: Aiming to capture the "unmet medical need" for once-monthly subcutaneous injection without loading dose or post-injection monitoring, citing a 4% relapse rate in follow-on studies (96% stability rate) as a key differentiator to address the ~13-14% LAI market share in schizophrenia.
• Pricing Strategy: Adopting a flat pricing model of $3,950 (WAC) per dose (contrasting with Uzeti's dose-dependent pricing) to avoid disincentivizing patients requiring higher doses, aiming to balance broad access with value preservation.
• Distribution: Launching via specialty pharmacy and hospital kits immediately; no J-code waiting period required; expect to achieve approximately 85% Medicaid coverage by the end of the first post-launch year.
• Competitive Landscape: Positioned as the only viable long-acting injectable olanzapine alternative; no direct competition from Relprev (Risperdal Consta) due to expiration and differing profiles.

Macro / Industry Outlook:

• Payer Access Dynamics: Acknowledges Medicaid approval timelines as a primary gating factor, noting state-by-state variation where some states approve immediately while others may take 12 months or longer.
• Clinical Trends: Anticipates physician demand for LAIs is growing due to recognition of relapse prevention and functional decline mitigation; expects market research to confirm high demand for the specific "no monitoring" feature set.
• Regulatory: FDA approval granted with no additional post-marketing commitments beyond standard pharmacovigilance for suspected Post-Injection Delirium Sedation Syndrome (PDSS).

Strategic Initiatives:

• Pivot to Growth: Welltrusa represents the materialization of the Phase 3 of Teva's "pivot to growth" strategy (initiated in 2023) to transition from a pure-play generic/defense company to a world-class biopharma by commercializing innovative products.
• Direct-to-Consumer (DTC) Campaign: Immediate launch of a direct DTC awareness campaign for Welltrusa, modeled after the successful re-mobilization strategy used for Uzeti, targeting patients, physicians, and families.
• Sales Force Readiness: Executing a nationwide launch meeting to prepare the commercial team on the co-located product strategy, leveraging the 80% physician overlap between existingUZeti and new Welltrusa targets.
• Patient Support: Deployment of a bespoke patient hub service to manage out-of-pocket costs and coordinate access, particularly for dual-eligible patients.

Risks and Headwinds to Outlook:

• Revenue Lag: Significant delay in revenue realization expected until H2 of the following year, dependent on the speed of Medicaid state-by-state approvals and hospital formulary placements.
• Safety Profile: Monitoring for Post-Injection Delirium Sedation Syndrome (PDSS) remains a requirement; the label explicitly notes dissolution rates and safety monitoring protocols compared to competitors.
• Metabolic Risks: Acknowledgment of the metabolic side effect risks associated with olanzapine (weight gain, etc.) similar to the oral version, which could impact long-term discontinuation rates, though the formulation aims to improve overall adherence.
• Market Uptake Uncertainty: While 13-14% LAI penetration in schizophrenia is cited as a target analog, actual conversion rates depend on physician adoption and patient willingness to switch from stable oral regimens.

Management Tone on the Future:

• Confidence Level: High confidence and enthusiasm; management describes the product as a "winning paradigm," a "real opportunity," and "exciting," emphasizing the privilege of addressing a "devastating disease."
• Strategic Validation: Views the launch as proof of the successful execution of the R&D pivot strategy, citing the "six to nine months" acceleration of the program and "right first time" approval.
• Synergy Outlook: Expresses strong belief in the "beautiful slipstream" effect of co-launching with Uzeti, leveraging existing commercial infrastructure to achieve broad market coverage quickly.

Miscellaneous:

• Technology Differentiation: Highlights the MedinCell platform's unique subcutaneous formulation which aggregates under the skin, achieving a 7% dissolution rate over 12 hours compared to 91% in 24 hours for other extended-release injections, ensuring rapid onset without post-injection monitoring.
• Patient Experience: Emphasis on removing logistical hurdles (loading doses, oral supplementation, post-injection observation) to improve the patient and physician experience compared to traditional intramuscular LAIs.